Notícias e Atividades da Surrozen

Surrozen é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Veja o organograma con seus 24 executivos principais

Biografias mais buscadas da Surrozen

• Craig Parker, Chief Executive Officer and Director
• Mary Haak-Frendscho, Director
• Anna Berkenblit, Director

Recentes movimentos de executivos em Surrozen

• Andrew Maleki ingressará na Companhia como Chief Financial Officer em 12 de nov. de 2025  (Notícia publicada em 10 de novembro de 2025).

Criar um alerta
para seguir os movimentos de executivos da Surrozen.

Surrozen possui 2.428 concorrentes concorrentes Lonza (Suíça), Vertex Pharmaceuticals (Estados Unidos) e Eurofins (Luxemburgo).

Popular M&A news in Biotecnologia

• Eli Lilly has announced the acquisition of AtaiBeckley  (publicado em 17 de julho de 2026).
• GSK adquiriu Nuvalent (publicado em 17 de julho de 2026).
• Clearside Biomedical has gone out of its bankruptcy protection  (publicado em 15 de julho de 2026).

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Robert Gould - Board Member da Fulcrum Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Surrozen

• Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis | Surrozen
• Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW) | Surrozen
• Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis | Surrozen
• Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Dise
• Surrozen Reports First Quarter 2022 Financial Results | Surrozen
• Surrozen to Present at the BofA Securities 2022 Healthcare Conference | Surrozen
• Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting | Surrozen
• Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results | Surrozen
• Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline | Surrozen
• Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference | Surrozen
• View more press releases Close

Redes sociais sobre Surrozen

• Surrozen na Wikipedia, Google News e Yahoo Finance
• Surrozen na LinkedIn, X (Twitter) e YouTube